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ABSTRACT 
Here, we report on the synthesis, conformational analysis and autoantibody binding properties 
of new sets of Rheumatoid arthritis (RA) specific biotin-peptide conjugates derived from 
filaggrin epitope peptides. The biotin with or without a linker was attached to the Cit or Arg 
containing epitope core (311TXGRS315) or epitope region 
(306SHQESTXGXSXGRSGRSGS324) peptide (where X = Cit), through an amide bond at the 
N- or C-terminal of the epitopes. Antibody binding was detected by indirect enzyme-linked 
immunosorbent assay (ELISA) using sera from RA, Systemic lupus erythematosus (SLE) 
patients as well as healthy individuals and the secondary structure of conjugates was 
investigated by electronic circular dichroism (ECD). We found that autoantibodies from RA 
patients recognize specifically both filaggrin epitope region 
(306SHQESTXGXSXGRSGRSGS324) and short epitope core (311TXGRS315) peptides. Our 
data also indicate that the positioning of the biotin label within a peptide sequence can 
markedly influence the antibody binding, but the length of the linker incorporated has 
essentially no effect on the recognition. ECD experiments demonstrate that the Arg/Cit 
change does not influence the solution conformation of the peptide conjugates. However, the 
presence and position of the biotin moiety has a pronounced effect on the conformation of the 
5-mer epitope core peptides, while it doesn’t alter the secondary structure of the 19-mer 
epitope region peptides. 
 
 
INTRODUCTION 
Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting 0.5-1.0% of the 
population worldwide and is characterized by chronic inflammation of the synovial joints. 
The current therapeutic strategy uses increasingly aggressive regimens early in the course of 
the disease. Thus, diagnosis of RA at a very early stage is crucial. 
Although the 1987 American College of Rheumatology (ACR) classification criteria 
for RA1 are used in clinical practice as diagnostic tool for RA, they are not very well suited 
for the diagnosis of early RA since at this time the clinical parameters are often not yet 
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manifest. Therefore a specific and sensitive (serological) marker, which is presented very 
early in the disease, is still needed. 
Various autoantibodies have been detected in sera from RA patients2, and were found 
to recognize citrullinated proteins or peptides: the so called anti-citrullinated protein/peptide 
antibodies (ACPA)3. In this report we are dealing with the filaggrin (filament-aggregating 
protein), which is one of the possible targets of these antibodies. The possibility that citrulline 
(Cit) residues might be present in the epitopes was investigated by Schellekens4. Several 
peptides were synthesized and an epitope region consisting of nineteen amino acids: 
306SHQESTRGRSRGRSGRSGS324 was found, which contained five arginine residues that 
might be target of citrullination. Numerous analogues were synthesized substituting arginine 
residues into citrulline or glutamine, glutamic acid, alanine and ornitin. The results suggested 
that not the absence of arginine, but the presence of citrulline specifically rendered the peptide 
autoantigenic. 
The best binding was obtained by the peptide once-substituted analogue at the 312 
position: 306SHQESTXGRSRGRSGRSGS324 (X= citrulline) (4). The cyclic derivative of this 
peptide – SHQ(CESTXGRSRGRC)cycloSGRSGS – was introduced as target antigen first to 
detect antibodies by ELISA in the clinical practice5. 
By systematic change of the arginine residues to citrulline an applying multipin 
ELISA approach with the RA patients’ sera6 we have identified an analogue, in which three 
Arg residues at positions 312, 314, 316 are replaced by Cit: 
306SHQESTXGXSXGRSGRSGS324. Furthermore, by N- and C-terminal shortening of the 
peptide sequence the minimum epitope peptide 311TXGRS315 was determined7. 
To detect the epitope binding we have designed a novel group of peptide conjugates 
with biotin. The biotin-avidin interaction, applied in ELISA to anchor the peptides to the 
plates, is one of the strongest non-covalent interactions known and it is stable toward a variety 
of harsh conditions8,9. Biotin-labeled peptides are widely used for example in affinity 
purification10, FRET-based flow cytometry11, solid-phase immunoassays12 and receptor 
localization13. 
The biotin, as label is most frequently attached directly to the N-terminal amino 
group14-16, and in only a few cases to the C-terminal17 of the B-cell epitope peptides. 
According to our knowledge no systematic studies were reported on the effect of the position 
of biotin on the antibody recognition of a peptide epitope. The distance between the epitope 
binding site and the biotin could also influence the interaction between the partners. To avoid 
this several linker types were developed and were utilized in the biotinylation methods: 
aminohexanoic acid (biotin LC, aminocaproic acid) 18-20, tetrapeptide – SGSG21 or β-alanine22 
was incorporated. Interestingly, essentially no data are available on the analysis of the effect 
of spacer moiety between biotin and B-cell epitope on antibody binding properties. 
The aim of the present work was to answer interesting and very important questions: 
how can the position of the biotin influence the antibody recognition and how fare should 
have been located the biotin from the minimum filaggrin epitope. We also examined that if 
the secondary structure is influenced by the biotin’s position. Based on our preliminary 
results7 we have synthesized a new set of N- and C-terminal biotin conjugates of peptides with 
Arg or Cit using various linkers between the epitope core and the biotin (Figure 1) to test the 
availability of the epitope as well as the specificity of antibody binding when the peptide 
conjugates are coupled to neutravidin coated plates. We were also interested to clarify the role 
of the secondary structure in antibody binding by ECD. 
Here we report on our findings that autoantibodies derived from RA patients recognize 
specifically both filaggrin epitope region (306SHQESTXGXSXGRSGRSGS324) and short 
epitope core (311TXGRS315) peptides (where X = Cit). Our data indicate that the positioning of 
the biotin label within a peptide sequence can markedly influence the antibody binding, but 
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the length of the linker has essentially no effect on the recognition. Based on ECD 
experiments we demonstrate that the Arg/Cit change does not influence the solution 
conformation of the peptide analogues. However, the presence and position of the biotin 
moiety has a pronounced effect on the conformation of the 5-mer epitope core peptides, while 
it doesn’t alter the secondary structure of the 19-mer epitope region peptides. 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials. All amino acid derivatives and resins (MBHA, Rink Amide MBHA) and coupling 
agents (N,N’-diisopropylcarbodiimide (DIPCI), N-diisopropyl-ethylamine (DIEA)) and 
scavengers (triisopropylsilan (TIS)) were purchased from IRIS Biotech GmbH (Marktredwitz, 
Germany) or Reanal (Budapest, Hungary), (benzotriazole-1-
yloxy)trispyrrolidinophosphonium hexaﬂuorophosphate (PyBOP) were purchased from 
NovaBiochem (Läufelfingen, Switzerland). Scavenger, coupling agents, and cleavage 
reagents (p-cresol, 1-hydroxybenzotriazole (HOBt), piperidine, trifluoroacetic acid (TFA), 
and hydrogen fluoride (HF)) were Fluka products (Buchs, Switzerland). Solvents for synthesis 
(dichloromethane (DCM), N,N’-dimethylformamide (DMF) and diethylether) were purchased 
from Molar Chemicals (Budapest, Hungary). Dimethylsulfoxide (DMSO) was from Sigma-
Aldrich Kft (Budapest, Hungary) and HPLC-grade acetonitrile (MeCN) and methanol 
(MeOH) were from Merck Kft (Budapest, Hungary). Biotin and biotinyl-6-aminohexanoic 
acid were Fluka products (Buchs, Switzerland) and the 4,7,10-trioxa-1,13-tridecane-diamino-
succinic acid (Ttds) was synthesized by us as described before23,24. Rabbit anti human IgG 
HRPO conjugate was purchased from Dako Agilent Technologies Company (Glostrup, 
Denmark). 
 
Synthesis of Free Peptides and N-terminal Biotinylated Peptide Conjugates. The non-
biotinylated and the N-terminal biotinylated 5-mer and 19-mer derivatives listed in Table 1 
were built up on Rink Amide-4-methylbenzhydrylamine (Rink Amide-MBHA) resin (0.56 
mmol/g coupling capacity) using Fmoc/tBu chemistry. Amino acids were coupled as Fmoc 
derivatives by the DIC/HOBt coupling method using a 3 molar excess over the resin capacity 
in DMF. The side chain of Glu residue was blocked with a tert-butyl ester protecting group 
and of His- and Gln residues were blocked with trityl group. Tert-Butylether group was 
applied for the protection of the OH function of Ser and Thr side chains, while the tert-
butyloxycarbonyl group was used for blocking the ε-amino group of Lys residue and 
pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf) group for the guanidino function of Arg. 
The N-terminal Fmoc group was removed by treatment of the resin-bound peptide with 
piperidine/DMF (30:70, v/v) mixture for 3 + 17 min at room temperature. The success of the 
coupling was controlled by ninhydrin reaction25. After removal of the last Fmoc group, the N-
terminus was acetylated by acetic anhydride and DIEA (5:5 eqv.) or biotinylated (peptide : 
biotin derivative : HOBt : PyBOP : DIEA = 1:3:3:3:10) in DMF/DMSO (25:75, v/v). After 
washing, the peptide-resin was dried in a desiccator. The peptides were cleaved from the resin 
with a mixture of TFA-water-TIS (95:2.5:2.5, v/v/v) at room temperature for 2 hrs. The crude 
products were purified by semipreparative RP-HPLC and the purified compounds were 
characterized by analytical RP-HPLC and ESI-ion trap mass spectrometry. The yields were 
50% to the resin capacity. 
 
Synthesis of C-terminal Biotinylated Peptide Conjugates. The C-terminal biotinylated 5-
mer and 19-mer conjugates listed in Table 1 were built up on 4-methylbenzhydrylamine 
(MBHA) resin (0.7 mmol/g coupling capacity) using Fmoc/tBu chemistry. Amino acids were 
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coupled as described above. An additional Lys (using Fmoc-Lys(Boc)-OH) was built into the 
C-terminus of the peptide to conjugate easily the biotin derivatives to its ε-amino group. After 
removal of the Boc protecting group from the side chain the εNH2 group of Lys was 
biotinylated (peptide : biotin derivative : HOBt : PyBOP : DIEA = 1:3:3:3:10) in 
DMF/DMSO (25 : 75, v/v). After washing, the remaining part of the sequence was built up by 
Fmoc strategy. The Fmoc group was removed by treatment of the resin-bound peptide with 
piperidine/DMF (30:70, v/v) mixture for 3 + 17 min. The success of the coupling was 
controlled by ninhydrin reaction25. After removal of the last Fmoc group, the N-terminus was 
acetylated by acetic anhydride and DIEA (5:5 eqv.) and after washing with DMF, methanol 
and diethylether, the peptide-resin was dried in a desiccator. The peptides were cleaved from 
the resin with anhydrous HF in the presence of p-cresol (HF-p-cresol 5 mL : 0.2 g) at room 
temperature. The crude products were purified by semipreparative RP-HPLC and the purified 
compounds were characterized by analytical RP-HPLC and mass spectrometry (Table 5). The 
yields were 40% to the resin capacity.  
 
Synthesis of C-terminal Ttds-containing and Biotinylated Peptide Conjugates. The C-
terminal biotinylated and Ttds-containing 5-mer and 19-mer conjugates listed in Table 1 were 
synthesized as described above, but with an additional Lys residue (using Boc-Lys(Fmoc)-
OH) on the C-terminus of the peptide. After removal of the Fmoc protecting group from the 
εNH2 function of Lys, Ttds linker was coupled as Fmoc-Ttds form by the DIC/HOBt coupling 
method using a 4 molar excess over the resin capacity in DMF. After washing, the Fmoc 
protecting group was cleaved from the Ttds residue and biotin derivatives were coupled 
(peptide : biotin derivative : HOBt : PyBOP : DIEA = 1:3:3:3:10) in DMF/DMSO (25:75, 
v/v). After washing and removing of the Boc protecting group by TFA, the remaining part of 
the sequence was built up by Fmoc strategy. The Fmoc group was removed by treatment of 
the resin-bound peptide with piperidine/DMF (30:70, v/v) mixture for 3 + 17 min. The 
success of the coupling was controlled by ninhydrin reaction25. After removal of the last Fmoc 
group, the N-terminus was acetylated by acetic anhydride and DIEA (5:5 eqv.) and after 
washing, the peptide-resin was dried in a desiccator. The peptides were cleaved from the resin 
with anhydrous HF in the presence of p-cresol (HF-p-cresol 5 mL : 0.2 g). The crude products 
were purified by semipreparative RP-HPLC and the purified compounds were characterized 
by analytical RP-HPLC and mass spectrometry. The yields were 35% to the resin capacity. 
 
High-Performance Liquid Chromatography (HPLC). Analytical RP-HPLC was performed 
on a Knauer (H. Knauer, Bad Homburg, Germany) system using a Phenomenex Jupiter C18 
column (250 mm × 4.6 mm) with 5 µm silica (300 Å pore size) (Torrance, CA) as a stationary 
phase. Linear gradient elution (0 min 0% B; 5 min 0% B; 50 min 90% B) with eluent A (0.1% 
TFA in water) and eluent B (0.1% TFA in acetonitrile-water (80:20, v/v)) was used at a flow 
rate of 1 mL/min. Peaks were detected at λ = 220 nm. The crude products were purified on a 
semipreparative Vydac 218 TP C18 column (250 mm × 10 mm) with 10 µm silica (300 Å 
pore size). The flow rate was 4 mL/min. The same eluents with a linear gradient of 20-60% B 
in 40 min were applied. 
 
Electrospray Ionization Mass Spectrometry (ESI-MS). Electrospray ionization mass 
spectrometry was performed with a Bruker Daltonics Esquire 3000+ mass spectrometer 
(Bremen, Germany), operating in continuous sample injection mode at 4 µL/min flow rate. 
Samples were dissolved either in a mixture of acetonitrile - water (1:1, v/v) or 50% MeOH, 
1% AcOH in water. Mass spectra were recorded in positive ion mode in the m/z 50-3000 
range. 
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Electronic Circular Dichroism (ECD) ECD spectra were recorded using Jasco 810 
polarimeter (Jasco Corporation, Japan) in quartz cell with an optical length of 0.02 cm at 
room temperature, under constant nitrogen flush. The polarimeter was calibrated with 
ammonium α-10-camphor-sulfonate. ECD spectra were measured in the region between λ = 
180-300 nm. The samples were dissolved at concentrations of 0.5 mg/ml in distilled water or 
in trifluoroethanol (TFE) (Aldrich, NMR grade). ECD band intensities are expressed in molar 
ellipticity ((θ)MR in deg cm
2/dmol where MR = mean residue). 
 
Indirect Enzyme-Linked Immunosorbent Assay (ELISA). For binding of biotinylated 
peptides, NeutrAvidin (5 µg/mL in phosphate buffered saline (PBS)) coated plates were used. 
After adding biotinylated peptides (1 µg/mL in PBS), wells were blocked by 40mM Tris-HCl, 
150 mM NaCl, 0,1% Tween, 0,5% BSA in deionizated water. After washing 3 times with 
0,5% Tween/PBS, sera samples were added (1:100 dilution) for an hour at 37°C. After 
washing and incubation with rabbit anti-human IgG (1:2000 dilution), conjugated to horse 
radish peroxidase, for an hour at 37°C, signal was developed by tetramethyl benzidin (10 
mg/mL, diluted in 0.1 M acetate buffer pH 5.5 adding 30% H2O2) for 5 min at room 
temperature. The reaction was stopped by 4M H2SO4. Absorbance was measured at 450 nm 
(correction wavelength set at λ = 620 nm) using a Labsystems Multiskan MS 
spectrophotometer. Optical density (OD) value was defined as the absorbance of each 
individual well, after substracting the background. Then OD ratios were calculated from the 
means of two parallel OD values as follows: the OD value of the citrulline containing peptide 
divided by the OD value of the arginine containing analogue. Cut off values for two peptide 
pairs were calculated from OD ratios of healthy samples (mean ± 2 SD (standard deviation)). 
Specificity was calculated as the percentages of healthy samples having an OD ratio below 
the cut off value as compared to total number of samples; while sensitivity was calculated as 
the percentage of RA patient samples giving an OD ratio higher than the cut off value, as 
compared to the total number of patient samples. For analyzing the data one-way ANOVA 
test (in case of normal distribution) and Kruskal-Wallis test (in other cases) was used for 
comparison. 
 
Patients. Sera samples from 16 age-matched (63±18 years) RA, 16 CCP (citrulline containing 
protein/peptide) negative, non-RA patient with other autoimmune disease (Systemic lupus 
erythematosus, SLE) and 16 age-matched (57±14 years) healthy individuals as controls were 
collected with ethical permission. The diagnosis of the disease was established on the basis of 
the revised diagnostic criteria for classification of rheumatoid arthritis, suggested in 1987 by 
the American Association for Rheumatism. All sera were previously tested for anti CCP 
positivity by Immunoscan CCPlus® kit (Eurodiagnostica)2 according to the manufacturer's 
instructions. Samples with results < 25 U/mL are defined as negative; samples ≥ 25 U/mL are 
defined as positive. 
 
 
RESULTS 
In order to understand the effect of biotinylation of a B-cell epitope on the binding of 
polyclonal autoantibodies from RA patients’ sera first we have prepared two sets of N- and C-
terminal biotinylated peptides. In these conjugates biotin was linked at the N- or at the C-
terminal part of either a pentapeptide epitope core (311TXGRS315) or a nineteenmer epitope 
region peptide (306SHQESTXGXSXGRSGRSGS324) without or with two types of spacer 
moieties (Figure 1). After appropriate characterization by RP-HPLC and MS analysis we have 
performed ECD studies to obtain information on the solution conformation of the above 
peptide conjugates in comparison with those of Arg containing 5-mer and 19-mer 
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counterparts in aqueous solution, as well as in ordered structure promoting TFE. The antibody 
binding properties of these groups of biotin peptide conjugates were studied by using sera 
from three groups of individuals. Namely, serum samples from healthy individuals, from RA 
patients and also from SLE patients were comparatively analyzed. 
 
Synthesis of the Conjugates. In both groups of biotinylated conjugates the N- or C-
terminal of the peptides were coupled with biotin using two types of spacers between the 
partners (Figure 2). We have utilized the long chain biotin in which biotin is extended by 
aminohexanoic acid (biotinyl-6-aminohexanoic acid) (Figure 1B and C). In conjugates with 
C-terminal biotin a Lys residue was introduced to the 5-mer or 19-mer peptide sequence and 
its ε-amino group was acylated with biotin or biotin derivative (Figure 1C-E). In addition, in 
conjugates with C-terminal biotin we have incorporated an oligoethylenglycol derivative 
spacer developed by us23,24 based on 4,7,10-trioxa-1,13-tridecane-diamino-succinic acid 
(Ttds). This moiety was positioned either between the epitope and the biotinylated Lys 
residue (Figure 1D) or between the Lys residue and the biotin (Figure 1E). Arginine 
containing analogues of both groups of peptides (306SHQESTRGRSRGRSGRSGS324 and 
311TRGRS315) were also synthesized and used as controls for the conformation as well as 
antibody binding studies. 
All peptides were synthesized by solid phase methodology using Fmoc-chemistry. The 
N-terminal biotinylation of the peptides were carried out via amid bond formation. In case of 
the C-terminal biotinylated conjugates a Lys was attached to the peptide and the biotin 
derivatives was coupled to the εNH2 group. In that case the N-terminals of the analogues were 
acetylated. It was a surprise, that the biotinylation step took at least 1 day, and in case of the 
C-terminal biotinylated derivatives repetition of the conjugation was needed. There can be a 
sterical reason of this difficulty because the εNH2 group of the lysine is not enough fare from 
the resin. 
All bioconjugates were purified by semipreparative RP-HPLC and the purified 
compounds were characterized by analytical RP-HPLC and ESI mass spectrometry (Table 1 
and Supporting Information, Figures S1 – S22). The purity of the compounds was over 95% 
and all compounds were obtained with 30 - 50% yield. 
 
Recognition of the N- and C-terminally biotinylated peptides by RA sera. 
The N-terminally biotinylated core epitope (p4) showed no binding to the patients’ 
sera and the insertion of aminohexanoic acid linker between the biotin and the peptide (p6) 
could not increase the antibody recognition. In contrast, all the C-terminal biotinylated core 
peptides (p8, p10, p12) were recognized by RA sera that were also positive in the most 
widely used diagnostic test, detecting anti-cyclic citrullinated peptide antibodies (anti-CCP2). 
Interestingly even with the increase of the length of the linker between the peptide and biotin, 
the strength of the binding decreases but the difference is not significant (by one-way 
ANOVA). The control healthy sera showed no reactivity to any of the peptides (Figure 3 and 
Table 2). 
In case of the epitope region peptide (306SHQESTXGXSXGRSGRSGS324) of filaggrin 
the N-terminal biotinylated compound (p16) and the C-terminal biotinylated molecule (p18) 
exhibited the same binding profile with the CCP2 positive sera. The distance between the 
peptide and the biotin (p18, p20, p22) has no marked influence (by one-way ANOVA) on the 
recognition (Figure 4 and Table 2). The control sera (healthy subjects and SLE patients) 
showed no reactivity to any of the peptides, the differences between the RA and control sera 
are significant (p < 0.05 by one-way ANOVA). 
To evaluate the specificity of the antibody recognition towards RA individuals, sera 
from patients with systemic lupus erythematosus (SLE), a different autoimmune disease and 
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serum samples of healthy subjects were also comparatively examined. These sera from SLE 
patients did not show any binding to the target antigens, indicating that the recognition of both 
the C-terminally biotinylated short epitope peptide and the N- or C-terminally biotinylated 
long epitope region peptide is specific for RA. 
In order to investigate the specificity and sensitivity and correlation of our results with 
data obtained by the standard (clinically) used methods, we have determined the relevant 
values in case of two peptide-conjugate (p10, p18). The results are the following: for the core 
epitope peptide (p10) cut off value was 1.352, the specificity was 98% and the sensitivity was 
51%. In case of the epitope region peptide (p18) the cut off value was 1.253, the specificity 
was 98% and the sensitivity was 51%. 
To test that our results are correlated to the standard or clinically used methods26, we 
have calculated Spearman correlation between the strength of binding (OD ratio) and the anti-
CCP2 titers. The recognition of peptides and the anti-CCP2 titer has shown a weak, but 
significant correlation. For the core epitope peptide (p10) the following values were obtained: 
r=0.3379 and p<0.0001 and for the epitope region peptide (p18) we found: r=0.2339, and 
p=0.0025 values. Stronger and significant correlations were detected (p<0.0001 in both cases 
with the MCV (mutated citrullinated vimentin) titers, for the core epitope peptide (p10) 
r=0.4562, and for the epitope region peptide (p18): r=0.3531. 
Collection of data covering peptide conjugates obtained with > 100 serum samples are 
in progress and the results will be published fully as a separate contribution in an assay 
development oriented journal. 
 
Electronic Circular Dichroism (ECD). 
ECD spectroscopy is a useful tool for monitoring the secondary structures of peptides 
and proteins. The ECD spectrum of periodic ordered (e.g. different helices, β-sheets), 
aperiodic ordered (different type of turns) structures, as well as the unordered structures, are 
well documented. ECD curve of an α-helix has a weak but broad negative band at λ = 222 nm 
assigned with the nπ∗ transition and an exciton couplet (ππ∗) localized at λ = 208 nm 
(negative band) and at λ = 192 nm (very intense positive band)27,28. ECD spectrum of β-sheet 
consists of a negative band near λ = 215 nm (nπ∗ transition) and a positive band near λ = 198 
nm (ππ∗ transition). 
Different turn-types have characteristic chiral contributions and their detection and 
discrimination is also possible by ECD spectroscopy. Among the three subgroups of turns, the 
contributions of β-turns to the circular dichroism has been studied in detail29. The spectrum of 
a type I or III β-turn resemble the ECD spectrum of α-helix where the band intensities are 
weaker, the ππ∗ bands are blue-shifted, and the nπ∗ bands are shifted to the longer 
wavelength region (C-like spectrum)30. 
Type II β-turns have similarity to the β-sheet spectrum but the bands are red-shifted 
by 5-10 nm. The γ-turn represents also a main type of folded secondary structures, an inverse 
γ-turn shows a negative nπ∗ band near λ = 230 nm and a ππ∗ a positive band near λ = 190 
nm31. It should be noted that ECD spectroscopy itself cannot distinguish between an inverse 
γ-turn and a type II β-turn. 
ECD spectrum with an intense negative band around λ = 200 nm and with a weak 
negative shoulder λ ~ 230 nm can be interpreted as a random coil (class U-spectrum). The 
same spectral features but with a weak positive shoulder can be identified as poly-proline type 
II helix (PPII) structure32,33. 
ECD of biotin-modified protein/peptide can be characterized by an extra positive band 
at λ ~ 240 nm if the biotin is interacting with the amino acid residue non-covalently34. 
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In solution the conformation of the biotinyl-6-aminohexanoic containing derivatives 
and the non-biotinylated peptides were studied by ECD spectroscopy. Spectra were recorded 
in water and in TFE, which is considered as ordered structure promoting solvent35. 
Considering that in ELISA experiments antibody binding occurs in aqueous medium, 
first we compared the solution conformations of the citrulline and arginine containing 
analogue pairs with or without biotin in water (Figure 5 and 7). 
The ECD spectra of pentapeptides representing the epitope core without biotin 
(311TXGRS315 vs. 311TRGRS315) indicate the presence of conformer-mixture composed of 
mainly unstructured conformers (Figure 5a) exhibiting at λ ~ 222 nm a weak and near λ ~ 196 
nm a strong negative band. The spectra of the N-terminal biotin conjugates (BiotLC-
311TXGRS315 vs. BiotLC-311TRGRS315) are characterized by two negative bands; a weaker at 
λ ~ 222 nm and a stronger one near λ ~ 198 nm as well as with, a weak positive band at λ ~ 
243 nm and intense positive ECD values at λ ~ 180 nm. These ECD curves represent higher 
ordered structures: in the conformational mixture a significant amount of β turns (mainly β I-
III turn) nearby the extended conformers appeared (Figure 5b). The presence of a positive 
band at λ ~ 243 nm is indicative for the biotin moiety34. The spectra of the C-terminal 
biotinylated epitope peptides (311TXGRS315K(BiotLC) vs. 311TRGRS315K(BiotLC)) are 
characteristic for PPII type helix and/or unstructured conformation (Figure 5c). There are two 
broad positive bands at λ ~ 239 nm and 215 nm and a strong negative band at λ ~ 195 nm, 
where the band λ ~ 239 nm as the biotin’s band could be also recognized. 
The comparison of spectral patterns of the three pentapeptide-pairs, the similar shapes 
indicate, that the arginine/citrulline change in a given pair does not influence significantly 
their conformation in water. However, small, but marked differences in the spectral 
characteristics (position and intensities of the positive bands) between the N- and C-terminally 
biotinylated peptides could well be documented. 
Next we have compared the ECD spectra of the above compounds in TFE and 
observed essential no differences in spectral features between the Arg- and Cit-containing 
analogues (data not shown). The spectra of citrulline containing free and biotin conjugated 
pentapeptides in TFE are presented in Figure 6. The ECD spectrum of biotin free epitope core 
peptide (311TXGRS315) showed predominantly β I-III turn conformation (Figure 6b: black 
color) with characteristic C-type spectrum36: a weak, blue-shifted helix spectrum with a 
positive band at λ = 186 nm and two negative bands at λ = 224 nm and at λ = 199 nm. The 
spectrum of the N-terminal biotinylated derivative (BiotLC-311TXGRS315) (Figure 6b: red 
color) may represent significant amount of β II turn conformers: there is a strong positive 
band at λ = 190 nm and a negative band near λ = 223 nm and appeared at λ = 243 nm the 
biotin’s positive band. The spectrum of the C-terminal biotinylated pentapeptide 
(311TXGRS315K(BiotLC)) represents a mixed set of conformers composed of β II turn (or γ 
turn) and unstructured conformation (Figure 6b: blue color) with two positive bands at λ = 
243 nm (a broad, very weak) and at λ = 196 nm (stronger one) and a negative band at λ = 225 
nm. The biotin’s band at λ = 243 nm could be also recognized. Like in the case of spectra 
recorded in water, we found marked differences in the spectral pattern (position and intensity 
of the bands) between the N- and C-terminally biotinylated peptides. 
The ECD spectra of the free and biotin conjugated epitope core peptides 
(311TXGRS315) recorded in water and also in TFE (Figure 6a,b) suggest that conformation of 
the compounds are very much dependent on the presence as well as position of the biotin-
moiety in both solvents. 
Next we have studied and compared the ECD spectra of the peptide-pairs covering the 
epitope region of filaggrin (306SHQESTXGXSXGRSGRSGS324) in water and also in TFE. It 
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is worth to mention that this 19-mer peptides comprise the 311TXGRS315 epitope core peptide 
studied above. 
In water we found minor difference (stronger negative band near λ ~ 197 nm) between 
the 19-mer peptide with Arg residues as compared to the one, which contained Cit at positions 
312, 314 and 316 (Figure 7a). Similarly the two peptides conjugated with biotin at their C-
terminal displayed almost the same kind of spectra with some alteration (near λ ~ 220 nm) 
(Figure 7c). We detected differences only in the intensities in case of the N-terminal 
biotinylated peptides (Figure 7b). This could indicate that the replacement of Arg by Cit 
induce no or only minor changes in the steric arrangement. Also in water the presence of the 
biotin in C-terminal position essentially does not influence the conformation (PPII and/or 
unstructered conformation) (Figures 7a vs. 7c) and the presence of biotin at the N-terminus 
resulted only limited changes in the population of conformers (appearance of some ordered 
structure nearby PPII and unordered conformation) (Figures 7a vs. 7b). The biotin’s band at λ 
~ 240 nm could not be recognized in any ECD spectra, which means that the biotin has no 
interaction with the peptide skeleton. Comparison of the ECD spectra of the above compound 
pairs in TFE we detected no major alterations in the pattern between the Arg- and Cit-
containing 19-mer peptides (data not shown). 
In TFE the spectral features of the ECD spectra of the 19-mer compounds without or 
with biotin (p14, p16, p18) (Figure 8b) reflect the presence of conformer mixture with a high 
populations of ordered (mainly helical) structures (a strong positive band at λ ~ 190 nm, two 
negative bands λ ~ 207 nm and λ ~ 220 nm), namely α-helix, β-sheet and β-turn are 
presented in different populations in case of each derivatives nearby random structure. The 
composition of conformers was confirmed with CDNN deconvolution-program37. 
The results of the ECD study of the epitope region peptide 
(306SHQESTXGXSXGRSGRSGS324) recorded in water and also in TFE (Figures 8a vs. 8b) 
indicate that the spectral pattern of the compounds (p14, p16, p18) essentially do not vary. 
Consequently these compounds could adopt similar 3D structure as detected by ECD 
regardless on the presence and position of biotin. This suggests that conformation of these 
compounds are very much less dependent on the presence and/or position of the biotin-
moiety. 
 
 
DISCUSSION 
Biotin is a frequently used label moiety, which plays an important role in various 
analytical methods, predominantly in immunoassays due to the strong biotin-avidin 
interaction38. Several biotinylation methods have been developed and the biotin 
peptide/protein conjugates are widely used. For example Zeng et al. synthesized N-terminal 
biotinylated peptides with a 6-aminohexanoic acid residue spacer for the examination of a B-
cell epitope of the luteinizing hormone releasing hormone39. The biotin-peptide conjugate 
(LHRH6–10) was able to inhibit the binding of anti-LHRH1–10 antisera to LHRH1–10 as detected 
by ELISA. Recently a new biotin-avidin mediated competitive ELISA was developed to 
detect residues of tetracyclines in milk (100µg/L) using biotin labeled rabbit anti-sheep IgG40. 
In another report Asp-hemolysin-related N-terminally biotinylated synthetic peptides were 
examined by flow cytometry that supposed to be potent inhibitors of platelet-activating 
factor16. Interestingly only one report described presents details about N- and C-terminally 
biotinylation17. For an epitope mapping study overlapping peptides of 10 amino acid residues 
covering the β-amyloid peptide 1–42 were prepared. One subset of peptides was biotinylated 
at the C-terminus, while the other set was biotinylated at the N-terminus. Unfortunately, the 
same oligopeptide was not labeled either on the N-terminal, or on the C-terminal. The rational 
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of the design of these conjugates were not explained. These conjugates were studied for 
monoclonal and polyclonal antibody binding by ELISA. 
Seemingly no systematic studies were reported so far on the effect of the position of 
biotin on the antibody recognition or on the comparison of the different biotinylation 
methods. 
In this report we describe the synthesis of N- and C- terminal biotin-peptide conjugates 
corresponding to a 19-amino acid long epitope region and also to a 5-amino acid long epitope 
derived from filaggrin with or without spacer structure. With this new set of peptides and their 
biotin conjugates we have studied how the position of the biotin and the distance between the 
biotin and the epitope core could influence the (auto)antibody recognition. 
Serum samples from RA patients, from healthy subjects and from SLE patients were 
comparatively examined. The results indicate that the binding of the C-terminally biotinylated 
epitope peptide (311TXGRS315) and both the C- or N-terminally biotinylated epitope region 
peptide (306SHQESTXGXSXGRSGRSGS324) is specific for RA. In sharp contrast with these 
results polyclonal antibodies derived from RA patients did not recognize the 5-mer peptide 
epitope conjugate with N-terminal biotin. 
In order to understand differences/similarities observed in the binding experiments, the 
secondary structure of free and biotin conjugated peptides was studied in details. Results 
clearly show that the arginine/citrulline change has no significant influence on the solution 
conformations neither of the 5-mer epitope nor of the 19-mer epitope region peptide in water 
and even in ordered structure promoting TFE. 
These studies suggest that the conformational properties of the N- and C-terminally 
biotinylated epitope core pentapeptide conjugates differ substantially. The type of secondary 
structure elements in the conjugate with C-terminal biotin resembles of a mixture of PPII type 
helix and/or unstructured conformers (in water) or a mixture of β II turn (or γ turn) and 
unstructured conformers (in TFE) and characteristically differs from conjugate with N-
terminal biotin, which has conformer mixture of a significant amount of β turns, mainly β I-
III turn (in water) or β II turn conformers (in TFE).  
On the other hand, ECD spectra recorded in water as well as in TFE demonstrate only 
minor differences in the conformational features of the epitope region 19-mer peptide 
conjugates with C- or N-terminal biotin. The secondary structure elements in both of the 
conjugates resemble PPII type helix and/or unstructured conformers (in water) or conformer 
mixture predominated by ordered structures (α-helix, β-sheet and β-turn) (in TFE). 
Data from the ECD studies suggest that the position of biotin in the 5-mer epitope 
peptide has a pronounced effect of secondary structure in solvents as studied, while in case of 
the 19-mer epitope region peptides the position of biotin has almost no influence on the 
secondary structure of the conjugates. 
Taken together the results of the indirect ELISA and ECD experiments two important 
features of antibody binding to synthetic peptide antigens corresponding to filaggrin are 
shown. First, as expected, only the citrulline containing peptides can be recognized by the 
CCP2 positive RA sera, however, the conformation data unraveled that the Arg/Cit change in 
the peptide sequence does not modify soundly the secondary structure of the peptide 
conjugates. It means that the primary structure of the epitope by modification of charges (e.g. 
replacement of three positively charged guanidino group of three Arg residues by neutral side 
chains of Cit) predominantly determines the antibody recognition and the contribution of the 
type of secondary structure could only be limited to the antibody binding. 
The second feature is that while in case of the filaggrin epitope region 19-mer 
conjugates there was no difference in the antibody recognition of the N- or C-terminal 
biotinylated derivatives, the position of biotin in the epitope core 5-mer conjugates 
significantly alters antibody binding. These findings are in harmony with observations derived 
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from the secondary structure studies. The conformation of the epitope region peptide 
(306SHQESTXGXSXGRSGRSGS324) does not change markedly due to the different 
biotinylation site, while the results of the ECD experiments suggest that in case of the 5-mer 
epitope core (311TXGRS315) the conformation influenced very much by the presence and 
position of the biotin. Thus, these factors drastically could affect the accessibility of the 
epitope core, the detection of the antibody binding phenomenon. 
 
 
CONCLUSIONS 
Novel N- or C-terminally biotinylated RA-specific peptide conjugates corresponding 
to the minimum epitope core or the epitope region of filaggrin with or without different linker 
moieties were prepared. The new compounds were tested by indirect ELISA using 
NeutrAvidin coating and the solution conformation of peptides in water and in ordered 
structure promoting solvent (TFE) was assessed by ECD. Data discussed above indicate that 
in case of the long 19-mer epitope region peptide (306SHQESTXGXSXGRSGRSGS324) the 
primary structure determines predominantly the recognition by RA-specific autoantibodies. 
We assume that in this case the biotinylation essentially does not influence the binding since 
the minimum epitope core (311TXGRS315) is located in the middle of the sequence, in a 
distance from both N- or C-terminal. In contrast, in case of the 5-mer epitope core peptide 
conjugate: both the primary and the secondary structure may affect the antibody binding. 
Furthermore, in the present study we proved that the positioning of the biotin label on a 
peptide sequence can profoundly influence its recognition by antibodies thus the sensitivity of 
an ELISA. Based on the results of this we propose an approach how to identify the best 
analogue of an epitope peptide of a given sequence for binding studies: biotinylate peptides 
both N-terminal and C-terminal, incorporate spacers of different lengths and types, and screen 
to determine the optimal combination of these elements to develop an efficient and sensitive 
antibody binding assay. 
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ABBREVIATIONS 
ACPA: anti-citrullinated peptide/protein antibodies 
BiotLC: biotinyl-6-aminohexanoic acid (longchain biotin) 
Boc: tButyloxycarbonyl 
BSA: bovine serum albumin  
CCP: cyclic citrullinated peptide 
DCM: dichloromethane 
DIEA: N-diisopropyl-ethylamine 
DMF: N,N’-dimethylformamide 
DMSO: dimethylsulfoxide 
ECD: electronic circular dichroism 
ELISA: enzyme-linked immunosorbent assay 
ESI-MS: electrospray ionization mass spectrometry 
Fmoc: fluorenylmethoxycarbonyl 
HF: hydrogenfluoride 
HOBt: 1-hydroxybenzotriazole 
HRPO: horse radix peroxidase 
MeOH: methanol 
OD: optical density 
PAD: peptidyl arginine deiminase 
PBS: phosphate buffered saline 
PyBOP: benzotriazole-1-yloxy)trispyrrolidinophosphonium hexaﬂuorophosphate 
RA: Rheumatoid arthritis 
RP-HPLC: reverse phase high-performance liquid chromatography 
SLE: systemic lupus erythematosus 
TFA: trifluoroacetic acid 
TFE: trifluoroethanol 
TIS: triisopropylsilan 
Ttds: 4,7,10-trioxa-1,13-tridecane-diamino-succinic acid 
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TABLES 
 
Table 1. Characteristics of the Conjugates and Free Peptides
a
 
  RP-HPLCb ESI-MSc 
Code Sequence* Rt (min) Mav 
calc. 
Mav 
exp. 
p1 Ac-TRGRS-NH2 13.1 616.7 616.5 
p2 Ac-TXGRS-NH2 13.1 617.7 617.5 
p3 Biotinyl-TRGRS-NH2 19.1 802.9 802.8 
p4 Biotinyl-TXGRS-NH2 18.3 803.9 803.7 
p5 BiotLC-TRGRS-NH2 16.2 914.1 914.0 
p6 BiotLC-TXGRS-NH2 16.5 915.1 915.0 
p7 Ac-TRGRSK(BiotLC)-NH2 17.1 1085.3 1085.6 
p8 Ac-TXGRSK(BiotLC)-NH2 17.1 1086.3 1086.6 
p9 Ac-TRGRSK(Biotinyl-Ttds)-NH2 18.0 1274.1 1274.2 
p10 Ac-TXGRSK(Biotinyl-Ttds)-NH2 17.6 1275.1 1275.2 
p11 Ac-TRGRS-Ttds-K(BiotLC)-NH2 18.4 1387.3 1387.4 
p12 Ac-TXGRS-Ttds-K(BiotLC)-NH2 18.5 1388.3 1388.4 
p13 Ac-SHQESTRGRSRGRSGRSGS-NH2 15.6 2086.2 2086.2 
p14 Ac-SHQESTXGXSXGRSGRSGS-NH2 15.6 2089.2 2089.3 
p15 BiotLC-SHQESTRGRSRGRSGRSGS-NH2 13.4 2383.6 2383.8 
p16 BiotLC-SHQESTXGXSXGRSGRSGS-NH2 13.1 2386.6 2386.7 
p17 Ac-SHQESTRGRSRGRSGRSGSK(BiotLC)-NH2 17.8 2554.8 2554.8 
p18 Ac-SHQESTXGXSXGRSGRSGSK(BiotLC)-NH2 17.9 2557.8 2557.9 
p19 Ac-SHQESTRGRSRGRSGRSGSK(BiotLC-Ttds)-NH2 18,8 2857.4 2857.5 
p20 Ac-SHQESTXGXSXGRSGRSGSK(BiotLC-Ttds)-NH2 19.1 2860.4 2860.5 
p21 Ac-SHQESTRGRSRGRSGRSGS-Ttds-K(BiotLC)-NH2 20.0 2857.4 2857.5 
p22 Ac-SHQESTXGXSXGRSGRSGS-Ttds-K(BiotLC)-NH2 20.0 2860.4 2860.5 
a RP-HPLC chromatograms and mass spectra are shown in the Supporting Information (S1-S24). 
b
 Column: Phenomenex Jupiter C18 (250 mm × 4.6 mm) with 5 µm silica (300 Å pore size); gradient: 0 min 0% 
B; 5 min 0% B; 50 min 90% B; eluents 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water (80:20, v/v) 
(B); flow rate: 1 mL/min; detection: λ = 220 nm. 
c
 Bruker Daltonics Esquire 3000+ ion trap mass spectrometer. 
* X = citrulline, standard one-letter code is used for the other amino acid residues; Ac = acetyl group; BiotLC = 
Biotinyl-6-aminohexanoic acid, Ttds = 4,7,10-trioxa-1,13-tridecane-diamino-succinic acid. 
 
 
Table 2. The interpretation of the OD ratio values of the conjugates 
Peptide pairs 
mean OD ratio 
p-value 
RA sera (CCP2+) SLE sera (CCP2-) Healthy sera 
p4/p3 0.59 n.d. 0.72 - 
p6/p5 0.56 n.d. 0.73 - 
p8/p7 47.91 0.89 0.56 p<0.001* 
p10/p9 35.21 0.95 0.61 p<0.001* 
p12/p11 23.98 n.d. 0.40 p<0.001* 
p16/p15 3.55 0.52 0.92 p<0.05** 
p18/p17 2.26 0.41 0.64 p<0.05** 
p20/p19 2.08 0.43 0.59 p<0.05** 
p22/p21 2.37 0.42 0.72 p<0.05** 
*Comparison of the C-terminal biotinylated 5-mer peptides and the N-terminal biotinylated conjugates using 
one-way ANOVA test (in case of normal distribution) and Kruskal-Wallis test (in other cases). 
**The data from the RA patients were compared with the data from the healthy controls analyzing by one-way 
ANOVA test (in case of normal distribution) and by Kruskal-Wallis test (in other cases). 
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FIGURES 
 
 
 
Fig. 1 Schematic presentation of the N- and C-terminal biotinylated forms. (A) N-terminal 
biotin conjugated peptide, (B) N-terminal biotinyl-6-aminohexanoic acid conjugated peptide, 
(C) C-terminal biotinyl-6-aminohexanoic acid conjugated peptide, (D) C-terminal biotinyl-6-
aminohexanoic acid conjugated peptide using 4,7,10-trioxa-1,13-tridecane-diamino-succinic 
acid (Ttds) linker, (E) C-terminal biotinyl-Ttds conjugated peptide. 
 
 
 
 
 
Fig. 2 Biotin derivatives and linker: (A) N-(+)-biotin, (B) N-(+)-biotinyl-6-aminohexanoic 
acid = BiotLC, (C) 4,7,10-trioxa-1,13-tridecane-diamino-succinic acid = Ttds 
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Fig. 3 Binding of antibodies from RA sera to peptides containing the minimum epitope 
(311TXGRS315) of filaggrin as detected by indirect ELISA. The peptides were biotinylated 
either at the N terminal (p3-p6) or the C terminal (p7-p12) position. The red drops represent 
the OD ratio of the peptides tested with CCP2 positive sera. Sera from healthy subjects were 
used as control (blue drops) and SLE sera were used as disease control (black drops). 
 
 
 
 
 
Fig. 4 Binding of anti-citrullinated peptide antibodies (ACPA) to peptides containing the 
epitope region (306SHQESTXGXSXGRSGRSGS324) of the filaggrin. The red drops represent 
the OD ratio of the peptides tested with the CCP2 positive sera. Sera from healthy subjects 
were used as control (blue drops) and SLE sera were used as disease control (black drops). 
 
 
Page 17 of 28
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 
 
Fig. 5 ECD spectra of the 311TXGRS315 epitope core peptide and its biotin conjugates in 
aqueous solution. (a) ECD spectra of the biotin free peptides (1, 2), (b) ECD spectra of the N-
terminal biotinylated conjugates (5, 6), (c) ECD spectra of the C-terminal biotinylated 
conjugates (7, 8). 
 
 
 
 
 
 
 
 
Fig. 6 ECD spectra of the 311TXGRS315 filaggrin epitope core and its biotin conjugates (a) in 
water and (b) in trifluoroethanol. 
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Fig. 7 ECD spectra of the 306SHQESTXGXSXGRSGRSGS324 filaggrin epitope region 
peptide in water. (a) ECD spectra of the biotin free peptides (13,14), (b) ECD spectra of the 
N-terminal biotinylated derivatives (15,16), (c) ECD spectra of the C-terminal biotinylated 
derivatives (17,18). 
 
 
 
 
 
Fig. 8 ECD spectra of the 306SHQESTXGXSXGRSGRSGS324 filaggrin epitope region and its 
biotin conjugates (a) in water and (b) in TFE. 
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Fig. 1 Schematic presentation of the N- and C-terminal biotinylated forms. (A) N-terminal biotin conjugated 
peptide, (B) N-terminal biotinyl-6-aminohexanoic acid conjugated peptide, (C) C-terminal biotinyl-6-
aminohexanoic acid conjugated peptide, (D) C-terminal biotinyl-6-aminohexanoic acid conjugated peptide 
using 4,7,10-trioxa-1,13-tridecane-diamino-succinic acid (Ttds) linker, (E) C-terminal biotinyl-Ttds 
conjugated peptide.  
177x101mm (300 x 300 DPI)  
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Fig. 2 Biotin derivatives and linker: (A) N-(+)-biotin, (B) N-(+)-biotinyl-6-aminohexanoic acid = BiotLC, (C) 
4,7,10-trioxa-1,13-tridecane-diamino-succinic acid = Ttds  
84x87mm (600 x 600 DPI)  
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Fig. 3 Binding of antibodies from RA sera to peptides containing the minimum epitope (311TXGRS315) of 
filaggrin as detected by indirect ELISA. The peptides were biotinylated either at the N terminal (p3-p6) or 
the C terminal (p7-p12) position. The red drops represent the OD ratio of the peptides tested with CCP2 
positive sera. Sera from healthy subjects were used as control (blue drops) and SLE sera were used as 
disease control (black drops).  
82x74mm (300 x 300 DPI)  
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Fig. 4 Binding of anti-citrullinated peptide antibodies (ACPA) to peptides containing the epitope region 
(306SHQESTXGXSXGRSGRSGS324) of the filaggrin. The red drops represent the OD ratio of the peptides 
tested with the CCP2 positive sera. Sera from healthy subjects were used as control (blue drops) and SLE 
sera were used as disease control (black drops).  
82x76mm (300 x 300 DPI)  
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Fig. 5 ECD spectra of the 311TXGRS315 epitope core peptide and its biotin conjugates in aqueous solution. (a) 
ECD spectra of the biotin free peptides (1, 2), (b) ECD spectra of the N-terminal biotinylated conjugates (5, 
6), (c) ECD spectra of the C-terminal biotinylated conjugates (7, 8).  
177x125mm (300 x 300 DPI)  
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Fig. 6 ECD spectra of the 311TXGRS315 filaggrin epitope core and its biotin conjugates (a) in water and (b) in 
trifluoroethanol.  
177x71mm (300 x 300 DPI)  
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Fig. 7 ECD spectra of the 306SHQESTXGXSXGRSGRSGS324 filaggrin epitope region peptide in water. (a) ECD 
spectra of the biotin free peptides (13,14), (b) ECD spectra of the N-terminal biotinylated derivatives 
(15,16), (c) ECD spectra of the C-terminal biotinylated derivatives (17,18).  
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Fig. 8 ECD spectra of the 306SHQESTXGXSXGRSGRSGS324 filaggrin epitope region and its biotin conjugates 
(a) in water and (b) in TFE.  
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